🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Batsheva Kerem

Hebrew University of Jerusalem

ORCID: 0000-0001-5722-0379
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation”.

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.06.003
N/A
1.6DataRank · unranked
53 citations

Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao +13 more

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2022.12.016
N/A
0.724DataRank · unranked
24 citations

Uta Griesenbach, Batsheva Kerem, John D. Lueck, Noemie Stanleigh, Yifat S. Oren +1 more

Oncogene-Induced Replication Stress Drives Genome Instability and Tumorigenesis

International Journal of Molecular Sciences(2017)10.3390/ijms18071339
N/A
0.520DataRank · unranked
31 citations

Batsheva Kerem, Dan Sarni

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.02.14.431123
N/A
0.241DataRank · unranked
4 citations

Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao +11 more

235 Reducing MUC5AC or MUC5B expression using antisense oligonucleotides as a therapeutic approach for cystic fibrosis and other muco-obstructive diseases

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01165-7
N/A
0DataRank · unranked
0 citations

C. Stampfer, R. Elgrabli, T. Blinder, Merav Ordan, S.A. Jubeh +6 more

3D genome organization contributes to genome instability at fragile sites

Nature Communications(2020)10.1038/s41467-020-17448-2
N/A
0DataRank · unranked
76 citations

Takayo Sasaki, Michal Irony Tur-Sinai, Karin Miron, Juan Carlos Rivera-Mulia, Brian Magnuson +4 more

236 SPL84, an antisense oligonucleotide modulating the 3849+10 kb C-T splicing defect, efficiently penetrates and restores CFTR function when treated through the apical side of primary human bronchial epithelial cells

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01166-9
N/A
0DataRank · unranked
0 citations

Yifat S. Oren, C. Stampfer, E. Ozeri-Galai, Gili Hart, Batsheva Kerem +1 more

290 Extending the success of elexacaftor-tezacaftor-ivacaftor to rare mutations—insights from CFTR structure and modulator binding

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01217-1
N/A
0DataRank · unranked
0 citations

N. Stanleigh, Michal Gur, Eitan Kerem, Michael Wilschanski, Batsheva Kerem